Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Towa Launches Task Force to Tackle Nitrosamine Impurities, Share Solutions with Peers
July 24, 2025
- Alloy Japan Teams with KSAC to Back University Startups’ Global Push
July 23, 2025
- FDA Panel Rejects Rexulti’s PTSD Bid: Otsuka/Lundbeck
July 23, 2025
- Santen’s Myopia Drug Ryjunea Now Available in Germany
July 23, 2025
- Moderna Drops Plan for mRNA API Site in Japan as Vaccine Demand Slumps
July 22, 2025
- Sanofi to Take Over Japan MA for Beyfortus from AstraZeneca
July 22, 2025
- Multi-Dose Wegovy Pen Now Available in Japan: Novo
July 22, 2025
- Enhertu Combo Gets Breakthrough Tag for First-Line HER2 Breast Cancer
July 22, 2025
- Nippon Chemiphar Signs On to Meiji-Daito Consortium as Talks Accelerate
July 22, 2025
- Ex-Finance Official Says Treating Obesity Could Lower Japan’s Healthcare Costs
July 22, 2025
- JRI Urges Reforms in Pricing and Reimbursement to Support Regenerative Medicine Ecosystem
July 18, 2025
- Astellas Partners with KISED to Support Korean Biotech Startups
July 18, 2025
- Kowa Picks Up Global Rights to Nicox’s Glaucoma Drug Excluding Asia
July 18, 2025
- Alnylam’s Amvuttra Could Become First-Line Therapy for ATTR-CM, Says Expert
July 18, 2025
- Otsuka Taps Autoimmune Diseases as Strategic Pillar for Long-Term Growth
July 17, 2025
- Nihon Medi-Physics to Deepen Theranostics Ties with Pharma under GE HealthCare
July 17, 2025
- Balversa Launched in Japan as 1st Genetically Targeted Drug for Bladder Cancer: J&J
July 17, 2025
- Towa Resumes Packaging Operations at Fire-Hit Yamagata Facility
July 17, 2025
- Nobelpharma’s Pediatric Sleep Aid Melatonin Wins Nod in China
July 17, 2025
- Fire Breaks Out at Towa’s Yamagata Plant, Production Halted at One Building
July 16, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…